<DOC>
	<DOCNO>NCT02325739</DOCNO>
	<brief_summary>Estimate maximum tolerate dose and/or recommend phase II dose efficacy FGF401 single agent combination PDR001 patient hepatocellular carcinoma single agent patient solid malignancy .</brief_summary>
	<brief_title>FGF401 HCC Solid Tumors Characterized Positive FGFR4 KLB Expression</brief_title>
	<detailed_description>Estimate maximum tolerate dose and/or recommend phase II dose detect Dose Limiting Toxicity efficacy FGF401 single agent combination PDR001 patient hepatocellular carcinoma single agent patient solid malignancy base RECIST 1.1 .</detailed_description>
	<criteria>1 . ECOG Performance Status ≤ 1 2 . Presence least one measurable lesion accord RECIST v1.1 . ci ) FGF401 single agentPhase I Phase II , Group 3 : Patients HCC advance solid tumor , progress despite standard therapy intolerant standard therapy , standard therapy exists . cii ) FGF401 single agentPhase II , Groups 1 2 : HCC patient previously treat sorafenib advance HCC document disease progression discontinuation sorafenib treatment , intolerance sorafenib treatment ciii ) FGF401 combination PDR001 : Advanced HCC patient receive 2 previous line systemic treatment one treatment must include sorafenib document disease progression discontinuation sorafenib treatment , intolerance sorafenib treatment 1 . Previous treatment selective FGF19FGFR4 target therapy and/or panFGFR inhibitor . 2 . Symptomatic CNS metastasis neurologically unstable require increase dos steroid control CNS disease . 3 . Patient range laboratory value define : Hematology Hemoglobin ≤ 9 g/dL ( SI Units : 90 g/L ) Platelet count &lt; 75000/mm3 Absolute neutrophil count ( ANC ) &lt; 1500/mm3 Chemistry Total bilirubin ≥ 2 mg/dL AST and/or ALT &gt; 3 x ULN Serum creatinine &gt; 1.5 x ULN and/or creatinine clearance ≤ 45 mL/min Coagulation : PT &gt; 4 second ULN INR &gt; 1.7 4 . Pregnant nursing ( lactate ) woman . Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>FGF401 , PDR001 , PD-1 , FGFR4 , FGF19 , HCC</keyword>
</DOC>